GOLD 2020
Recommends LAMA/LABA as a first-line initial treatment option for symptomatic COPD patients with severe breathlessness,* regardless of exacerbation risk.1¶¶¶§§§‡‡‡
Recommends LAMA/LABA as a first-line initial treatment option for symptomatic COPD patients with severe breathlessness,* regardless of exacerbation risk.1¶¶¶§§§‡‡‡
Recommends LAMA/LABA over LAMA or LABA monotherapy in patients with COPD who complain of dyspnoea or exercise intolerance.2
See how John struggles with dyspnoea during physical activities at work and learn how SPIOLTO® RESPIMAT® can provide a solution.
Watch John's storyNot recommended for the majority of COPD patients as initial treatment1†
Not recommended as initial maintenance treatment1
of COPD patients receive inhaled corticosteroids in practice23,27,28
of patients with COPD exacerbate infrequently or not at all, while up to 82% suffer from dyspnoea7,29
Use of inhaled corticosteroid-containing therapies‖‖‖ should be limited as they can expose patients to the risk of side effects, such as pneumonia, diabetes, candidiasis, dysphonia, cataracts and osteoporosis11,12
Before addition of inhaled corticosteroid to LAMA/LABA, GOLD 2020 recommends assessing inhaler technique, adherence,and the role of non-pharmacological approaches1
LAMA/LABA has demonstrated superiority in patient outcomes compared with LABA/inhaled corticosteroid6,9 and non-inferiority to LAMA/LABA/ICS in risk of exacerbations8,16,21
LAMA/LABA/ICS may only benefit a small subset of patients21
Learn more